海外有望企業情報OncoRevive

がん領域における治療モニタリングの課題に対し、ナノテクノロジーを活用した独自の診断キットを提供している。単一の血液サンプルから複数のバイオマーカーを同時解析できる点が特徴である。検査結果は最短2時間で提供され、1件当たり約1,000米ドルと低価格である。追加設備を必要とせず、高頻度の治療効果および再発モニタリングを可能にする。

OncoRevive solution addresses the critical "monitoring gap" in oncology with their proprietary diagnostic kit. The kit is a nanotechnology-enabled liquid biopsy that simultaneously analyses genomic, proteomic, and glycomic biomarkers from a single blood sample. While current "single-omic" tests are slow and prohibitively expensive, OncoRevive’s patented bioanalytical approach provides a 3D view of tumour evolution. Their primary competitive advantage is the speed and accessibility of the product. OncoRevive's actionable clinical reports can be delivered in under 2 hours (compared to the 14-day industry average) and are priced at $1,000 per test (4x less than other liquid biopsy tests). This enables high-frequency, longitudinal monitoring that can catch cancer recurrence months before it becomes visible on traditional imaging. Additionally, they use commercial instruments to run the tests, which means extra training and equipment costs aren't necessary for labs.